- Home
- » Tags
- » Talazoparib
Top View
- Listing of Trials for Financial Conflict of Interest with Entity
- Appendix B - Product Name Sorted by Applicant
- Perioperative Medication Management - Adult/Pediatric - Inpatient/Ambulatory Clinical Practice Guideline
- Peer Reviewed Publications for 2020 (Pdf)
- List Item Applications for New Human Medicines Under Evaluation by the CHMP
- An Overview of the Recently Approved Small-Molecules Anticancer Drugs in the Past Decade
- Small Molecules in Targeted Cancer Therapy: Advances, Challenges, and Future Perspectives
- Modifying Chemotherapy for the Older Patient
- PARP Inhibitors Talazoparib and Niraparib Sensitize Melanoma Cells to Ionizing Radiation
- Mechanisms of Chemotherapy Resistance in Triple-Negative Breast Cancer—How We Can Rise to the Challenge
- Synergistic Activity of PARP Inhibition by Talazoparib (BMN 673) with Temozolomide in Pediatric Cancer Models in the Pediatric Preclinical Testing Program Malcolm A
- 11-14 February 2019 PRAC Meeting Minutes
- Focus on Triple-Negative Breast Cancer: Potassium Channel Expression and Clinical Correlates
- Separately Chargeable Drugs List
- PARP Inhibitors in Small-Cell Lung Cancer: Rational Combinations to Improve Responses
- Radiosensitization Effect of Talazoparib, a Parp Inhibitor, On
- Antiproliferative and Carbonic Anhydrase II Inhibitory
- BMN 673), an Oral PARP Inhibitor, in Patients with Advanced Solid Tumors and Deleterious BRCA Mutations
- PARP Inhibitors for Small Cell Lung Cancer and Their Potential for Integration Into Current Treatment Approaches
- Talzenna, INN-Talazoparib
- PARP Inhibitors: Their Role Across Tumor Types
- Justification
- Response of Breast Cancer Cells to PARP Inhibitors Is Independent of BRCA Status
- Adult Antiemetic Management of Chemotherapy-Induced Nausea
- State and Specialty Pharmacy Drug Reimbursement Rates
- ATC-Index Mit DDD-Angaben Für Deutschland Im Jahre 2019
- Appendix a - Product Name Index
- Emetogenic Potential of Antineoplastic Agents
- Therapeutic Potential of PARP Inhibitors in the Treatment of Gastrointestinal Cancers
- Pdf/2009-10/Firmagon - Ct-6725.Pdf 58
- SUTTER HEALTH PLUS FORMULARY Drug List for HMO Members – Effective September 1, 2021
- Oncology Proposal
- 22161A 47136A FINAL Specialty Pipeline Drugs to Watch Q4 2018 KD
- Secondary Cancers: Education, Postgraduate Healthcare What the Pharmacist Education, Inc • Dr
- Patient Support Program & Patient Assistance Enrollment Form
- Beschlussfassung Der Sitzung Der Arbeitsgruppe ATC/DDD Des KKG
- Restricted Delivery of Talazoparib Across the Blood–Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma Sani H
- 211651Orig1s000
- Combination of Talazoparib and Palbociclib As a Potent Treatment Strategy in Bladder Cancer
- Emerging Patterns in the Development of Medicines in Paediatric Oncology
- Talazoparib for Locally Advanced And/Or Metastatic Breast Cancer with Germline BRCA 1/2 Positive Mutation
- Approved Drugs • the Food and Drug Administration (FDA) Has Approved
- Emetic Risk of Single Intravenous Antineoplastic Agents in Adults
- AHFS Pharmacologic-Therapeutic Classification System
- Standard Oncology Criteria Policy Number: Pending
- FEP 5 Tier Managed Rx Drug Formulary (807) Basic Option
- Talazoparib (Talzenna®) EOCCO POLICY
- Supplementary Table 1: List of Drugs and Their Binding Energies to ACE and ACE2
- Medicines for Free
- An Open Access Database of Licensed Cancer Drugs Pan Pantziarka 1,2, §, Rica Capistrano 1, Arno De Potter 3, Liese Vandeborne 1, Gauthier Bouche 1
- TAG Mail – 19 December 2019 REPORTS and PUBLICATIONS – AUSTRALIA
- Appendix a 2017 Financial Report Financial Review Pfizer Inc
- Smart Approaches for the Effective Treatment of Breast Cancer
- Analysis of PARP Inhibitor Toxicity by Multidimensional fluorescence Microscopy Reveals Mechanisms of Sensitivity and Resistance
- NHS Grampian Formulary Group Decisions for SMC Advice Published April 2020 to March 2021
- Do Not Tube List
- Development of Poly(ADP-Ribose) Polymerase Inhibitors in the Treatment of BRCA-Mutated Breast Cancer
- All ETCTN Trials
- Receptor Tyrosine Kinases-Mediated Acquired Parp Inhibitor Resistance in Breast Cancer
- 2020 Fully Insured Advanced Control Plan
- Translating Discoveries Into Cures for Children with Cancer
- Oncology Agents
- Partnering with PARP Inhibitors in Acute Myeloid Leukemia with FLT3-ITD T ∗ Anna J
- November 2020
- Induced Nausea and Vomiting
- Pfizer Reports Second-Quarter 2019 Results
- Assessment Report Talzenna